fda compounding semaglutide warning letters news Democratic lawmakers are pressing the Trump administration to disclose who received special access to Eli Lilly's investigational obesity drug retatrutide. Sen. Maggie Hassan (D-N.H.) sent a letter to HHS Secretary Robert F FDA issued 25 warning letters

The PM packet targets gut balance, recovery, and structural health overnight

Find out how to build a weight-loss plan that actually works postpartum.

Patent law is only one part of a much broader equation.The growing burden of diabetes across Africa provides an opportunity to rethink how intellectual property, public health and industrial policy interact before the continent faces another access crisis.The legal tools already exist.The more difficult question is whether governments are prepared to use them and whether the international community is willing to support a model of pharmaceutical innovation that rewards research while recognising that access to essential medicines is, ultimately, a matter of public interest.This is a co-published article, originally published on WIPR.

We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first t...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.

A public health expert explains how GLP-1 drugs have changed the way healthcare providers understand and treat obesity.